LynnAKohlmeierMD

Osteoporosis & Bone Metabolism Medicine, Parathyroid, Pituitary Disorders & Neuroendocrinology, Thyroid

Director

Dr. Kohlmeier is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

Efficacy and Safety of TransCon PTH in Adults with Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial.
Bart L Clarke, Aliya A Khan, Mishaela R Rubin, Peter Schwarz, Tamara Vokes
The Journal of Clinical Endocrinology and Metabolism. 2024-10-08
1 citations
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial.
Lars Rejnmark, Elvira O Gosmanova, Aliya A Khan, Noriko Makita, Yasuo Imanishi
Advances in Therapy. 2024-06-01
3 citations
Patients' preferences for fracture risk communication: the Risk Communication in Osteoporosis (RICO) study.
Charlotte Beaudart, Mitali Sharma, Patricia Clark, Saeko Fujiwara, Jonathan D Adachi
Osteoporosis International. 2024-03-01

A First for Hypoparathyroidism — Yorvipath (Palopegteriparatide) Earns FDA NodAugust 22nd, 2024
FDA OKs Once-Daily Injection for HypoparathyroidismAugust 12th, 2024
Medimaps Group at RSNA 2022: Providing the Full Bone-Health PictureNovember 21st, 2022